General Information of Drug (ID: DMAR4ZF)

Drug Name
5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole Drug Info
Synonyms
CHEMBL352049; 5-Methyl-2-pyridin-2-yl-1H-benzoimidazole; 7471-12-7; NSC403547; AC1L83HW; TimTec1_008296; 5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole; SCHEMBL124267; SCHEMBL12119033; DTXSID20323304; HMS1557J02; CCG-24525; BDBM50180733; ZINC12481420; AKOS002999038; AKOS000636609; NSC-403547; BAS 06347449; 6-methyl-2-pyridin-2-yl-1H-benzimidazole; 6-Methyl-2-(2-pyridyl)-1H-benzimidazole; KB-249126; US8748618, LD-2-11; 6-methyl-2-pyridin-2-yl-1h-benzo[d]imidazole
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
345772
CAS Number
CAS 7471-12-7
TTD Drug ID
DMAR4ZF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beloranib DM71CK8 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
D-Methionine DMMKGBP N. A. N. A. Phase 3 [3]
ZGN-1061 DM9KB7A Type 2 diabetes 5A11 Phase 2 [4]
M8891 DMZ9NVP Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
SDX-7320 DMU0Q6L Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PPI-2458 DMSAQBC Autoimmune diabetes 5A10 Phase 1 [6]
TNP-470 DMT0QK8 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [7]
2-Methyl-2-Propanol DMHM5GJ Discovery agent N.A. Investigative [3]
2-(phenylsulfonamido)-5-propylbenzoic acid DMDGAHO Discovery agent N.A. Investigative [8]
5-p-Tolyl-1H-[1,2,3]triazole DM2W0AD Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Methionine aminopeptidase 2 (METAP2) TTZL0OI MAP2_HUMAN Inhibitor [1]

References

1 Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
2 2011 Pipeline of Zafgen.
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab. 2020 Jul;22(7):1215-1219.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. Drug Metab Dispos. 2013 Apr;41(4):814-26.
7 Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15;63(22):7861-9.
8 Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
9 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo. J Med Chem. 2005 Sep 8;48(18):5644-7.